Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.

Breast cancer research : BCR | 2014

Activation of the phosphatidylinositol 3-kinase (PI3K) pathway in estrogen receptor α (ER)-positive breast cancer is associated with reduced ER expression and activity, luminal B subtype, and poor outcome. Phosphatase and tensin homolog (PTEN), a negative regulator of this pathway, is typically lost in ER-negative breast cancer. We set out to clarify the role of reduced PTEN levels in endocrine resistance, and to explore the combination of newly developed PI3K downstream kinase inhibitors to overcome this resistance.

Pubmed ID: 25212826 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: R01 CA94118
  • Agency: NIAID NIH HHS, United States
    Id: AI036211
  • Agency: NCRR NIH HHS, United States
    Id: S10RR024574
  • Agency: NCI NIH HHS, United States
    Id: P30CA125123
  • Agency: NCI NIH HHS, United States
    Id: R01 CA151962
  • Agency: NIAID NIH HHS, United States
    Id: P30 AI036211
  • Agency: NCI NIH HHS, United States
    Id: P50 CA058183
  • Agency: NCRR NIH HHS, United States
    Id: S10 RR024574
  • Agency: NCI NIH HHS, United States
    Id: R01 CA094118
  • Agency: NCI NIH HHS, United States
    Id: P50 CA58183
  • Agency: NCI NIH HHS, United States
    Id: P30 CA125123
  • Agency: NCI NIH HHS, United States
    Id: P50 CA58207
  • Agency: NCI NIH HHS, United States
    Id: P50 CA058207

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


AstraZeneca PheWAS Portal (tool)

RRID:SCR_021643

Repository of gene phenotype associations for phenotypes derived from electronic health records, questionnaire data, and continuous traits computed on exomes released by UK Biobank. Repository was made available by AstraZeneca for public research.

View all literature mentions

T-47D (tool)

RRID:CVCL_0553

Cell line T-47D is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions